Inhaled gene therapy trial aims to tackle root cause of cystic fibrosis
NCT ID NCT07485543
Summary
This early-stage study is testing a new inhaled therapy called BMD003 in Chinese patients aged 12 and older with cystic fibrosis. The therapy uses mRNA to help lung cells produce a needed protein. The main goals are to see if the treatment is safe and to look for early signs that it might improve lung function and quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.